{
    "url_original": "https://www.wsj.com/articles/sanofi-bets-on-mrna-vaccines-after-covid-19-pandemic-shows-worth-11624953601?mod=business_lead_pos3",
    "url": "sanofi-bets-on-mrna-vaccines-after-covid-19-pandemic-shows-worth-11624953601",
    "title": "Sanofi Bets on mRNA Vaccines After Covid-19 Pandemic Shows Worth",
    "sub_head": "One of the world’s biggest vaccine makers, it plans to invest some $477 million a year to catch up in the new gene-based technology",
    "category_1": "Business",
    "category_2": "Health Care",
    "time": "2021-06-29 04:00:00",
    "body": "Sanofi SA  said it plans to build a messenger RNA vaccine business, the latest big drugmaker to embrace the technology.<br />The French pharmaceutical company, one of the world’s biggest vaccine makers by sales, said Tuesday that it would invest €400 million, equivalent to $477 million, a year in mRNA vaccine research, starting immediately.<br />The drugmaker said it expects the investment to produce at least six new candidate vaccines in human testing by 2025.<br />The move is a sign of how mRNA technology, which hadn’t produced an approved product before the pandemic but is now a leading source of Covid-19 shots, is reshaping the vaccine industry.<br />“During the Covid-19 pandemic, mRNA technologies demonstrated potential to deliver new vaccines faster than ever before,” Jean-François Toussaint, R&D chief at Sanofi Pasteur, the company’s vaccine division, said in a statement"
}